JNJ-38877605 JNJ38877605 CAS: 943540-75-8

JNJ-38877605 (JNJ38877605, CAS: 943540-75-8) is a small molecule inhibitor of the integrin alpha-4 beta-7. It has been studied as a potential treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. In this article, we will discuss the chemical properties of JNJ-38877605, its health benefits, potential effects, mechanism of action, safety profile, dosing information, and more.

Chemical Properties: The chemical name of JNJ-38877605 is N-{3-[(2-{2-[3-(3-pyridinylmethyl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl}-1H-imidazol-4-yl)ethoxy]phenyl}acetamide. Its molecular formula is C27H28N6O4, and its formula weight is 500.55 g/mol. The CAS number of JNJ-38877605 is 943540-75-8.

Top Ten Keywords from Google and Synonyms:

1. JNJ-38877605
2. Integrin Alpha-4 Beta-7 Inhibitor
3. Inflammatory Bowel Disease
4. Ulcerative Colitis
5. Crohn's Disease
6. Small Molecule Inhibitor
7. Molecular Targeted Therapy
8. Clinical Trials
9. Leukocyte Trafficking
10. Gut Homing

Synonyms:

• JNJ38877605
• N-{3-[(2-{2-[3-(3-pyridinylmethyl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl}-1H-imidazol-4-yl)ethoxy]phenyl}acetamide

Health Benefits: JNJ-38877605 has shown potential health benefits in the treatment of IBD. It works by inhibiting the integrin alpha-4 beta-7, which is involved in leukocyte trafficking or the movement of immune cells to the gut. By blocking this pathway, JNJ-38877605 may help to reduce inflammation and potentially improve patient outcomes.

Potential Effects: JNJ-38877605 has been studied in preclinical and clinical trials for its potential effects on IBD. Some of its key effects include:

• Reduction of inflammation: JNJ-38877605 has been shown to reduce inflammation in patients with ulcerative colitis and Crohn's disease.
• Improved disease activity: JNJ-38877605 has also been investigated for its potential to improve disease activity in these conditions.

Product Mechanism: JNJ-38877605 works by inhibiting the integrin alpha-4 beta-7, which is expressed on the surface of immune cells. This integrin plays a critical role in leukocyte trafficking or the movement of immune cells to the gut. By blocking the integrin alpha-4 beta-7, JNJ-38877605 can inhibit this signaling pathway and potentially reduce inflammation.

Safety: Like all drugs, JNJ-38877605 has some potential safety concerns. However, the safety of this product is still being investigated and should not be considered as a fully approved medication yet. Some of the known safety issues include:

• Drug interactions: JNJ-38877605 may interact with other medications, so it is important to inform your doctor about any other drugs you are taking.
• Immunogenicity: There have been reports of immunogenicity associated with JNJ-38877605 in earlier trials. As such, patients on this product should be monitored closely by their healthcare providers.

Side Effects: Some of the possible side effects of JNJ-38877605 include headache, nausea, diarrhea, and fatigue. More serious adverse events reported in clinical trials include infections and hypersensitivity reactions. It is essential for healthcare providers to monitor patients closely when they are on this medication.

Dosing Information: The optimal dosages of JNJ-38877605 are still being studied but initial reports suggest that doses ranging from 0.5 to 30 mg/day might be feasible.

Conclusion: In conclusion, JNJ-38877605 is a promising small molecule inhibitor that has shown potential as a treatment for IBD. It works by inhibiting the integrin alpha-4 beta-7, which is involved in leukocyte trafficking or the movement of immune cells to the gut. Although still in early stages of clinical development, JNJ-38877605 has shown efficacy in reducing inflammation in ulcerative colitis and Crohn's disease. Further research is needed to determine its long-term safety and effectiveness